

**Meeting of the Anesthetic and Life Support Drugs Advisory Committee
May 16, 2002**

<u>Agenda</u>		
8:00 – 8:15	Welcome and Introductions	Cynthia McCormick, MD
8:15 – 8:20	Conflict of Interest Statement	Advisors and Consultant Staff
8:20 – 9:20	Open Public Hearing	Public Comments
9:20 – 9:30	General Clinical/Regulatory Issues in Development of Drugs Intended for Treatment of a Chronic Illness	Sharon Hertz, MD
9:30 – 9:40	Specific Clinical/Regulatory Issues in Development of Drugs for Peripheral Neuropathy and Neuropathic Pain	Gerald Dal Pan, MD, MHS
9:40 – 10:10	Scales Used in the Evaluation of Peripheral Neuropathy	Eva Feldman, MD
10:10 – 10:15	Questions	
10:15 – 10:30	Break	
10:30 – 11:00	Electrophysiologic Tests Used in the Evaluation of Peripheral Neuropathy and Neuropathic Pain	David Cornblath, MD
11:00 – 11:05	Questions	
11:05 – 11:35	Skin Biopsy in the Evaluation of Peripheral Neuropathy and Neuropathic Pain	Justin McArthur, MB, BS, MPH
11:35 – 11:40	Questions	
11:40 – 12:55	Lunch Break	
12:55 – 1:25	Discussion of Entry Criteria for Clinical Trials for Diabetic Peripheral Neuropathy	
1:25 – 1:55	Discussion of Clinical Efficacy Outcomes in Peripheral Neuropathy Trials (for disease modification and/or non-pain symptom reduction)	
1:55 – 2:25	Discussion of Duration of Clinical Trials for Peripheral Neuropathy Trials	
2:25 – 2:40	Break	
2:40 – 3:10	Point-Counterpoint: Extrapolation of Findings from One Type of Neuropathic Pain to Another Neuropathic Pain Condition	Michael Rowbotham, MD and Robert Dworkin, MD
3:10 – 3:20	Questions	
3:20 – 3:50	Discussion of Clinical Efficacy Outcomes in Neuropathic Pain Trials	
3:50 – 4:20	Discussion of Extrapolation of Findings from One Type of Neuropathic Pain to Another	
4:20 – 4:50	Discussion of Duration of Clinical Trials for Peripheral Neuropathy Trials	
4:50 – 5:05	Wrap-up	
5:05	Adjourn	
